Connection

THOMAS LLOYD to Male

This is a "connection" page, showing publications THOMAS LLOYD has written about Male.
Connection Strength

0.342
  1. Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis. Neurology. 2023 03 28; 100(13):e1406-e1417.
    View in: PubMed
    Score: 0.032
  2. TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. Elife. 2020 12 10; 9.
    View in: PubMed
    Score: 0.028
  3. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018 05 03; 173(4):958-971.e17.
    View in: PubMed
    Score: 0.023
  4. Fifteen-year longitudinal follow-up of a patient with severe early-onset Charcot-Marie-Tooth disease type 2A. Muscle Nerve. 2018 05; 57(5):E126-E128.
    View in: PubMed
    Score: 0.023
  5. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017 Apr 11; 88(15):1454-1460.
    View in: PubMed
    Score: 0.021
  6. A Case of Morvan Syndrome Mimicking Amyotrophic Lateral Sclerosis With Frontotemporal Dementia. J Clin Neuromuscul Dis. 2016 Jun; 17(4):207-11.
    View in: PubMed
    Score: 0.020
  7. Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging. 2016 12; 44(6):1513-1521.
    View in: PubMed
    Score: 0.020
  8. Characterizing local antibody responses in the muscle of inclusion body myositis patients. J Autoimmun. 2025 Jun; 154:103437.
    View in: PubMed
    Score: 0.009
  9. Pathological autoantibody internalisation in myositis. Ann Rheum Dis. 2024 10 21; 83(11):1549-1560.
    View in: PubMed
    Score: 0.009
  10. Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis. Nat Aging. 2024 Jul; 4(7):969-983.
    View in: PubMed
    Score: 0.009
  11. Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants. Brain. 2023 10 03; 146(10):4336-4349.
    View in: PubMed
    Score: 0.008
  12. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 10; 22(10):900-911.
    View in: PubMed
    Score: 0.008
  13. c-Jun N-Terminal Kinase Promotes Stress Granule Assembly and Neurodegeneration in C9orf72-Mediated ALS and FTD. J Neurosci. 2023 04 26; 43(17):3186-3197.
    View in: PubMed
    Score: 0.008
  14. Prevalence of avascular necrosis in idiopathic inflammatory myopathies: a single-centre experience. Rheumatology (Oxford). 2022 03 02; 61(3):936-942.
    View in: PubMed
    Score: 0.008
  15. Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis. Ann Neurol. 2022 03; 91(3):317-328.
    View in: PubMed
    Score: 0.008
  16. Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis Rheumatol. 2022 02; 74(2):358-364.
    View in: PubMed
    Score: 0.007
  17. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 03 23; 96(12):e1595-e1607.
    View in: PubMed
    Score: 0.007
  18. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain. 2020 12 01; 143(12):3589-3602.
    View in: PubMed
    Score: 0.007
  19. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis. 2020 09; 79(9):1234-1242.
    View in: PubMed
    Score: 0.007
  20. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020 03 03; 94(9):e884-e896.
    View in: PubMed
    Score: 0.007
  21. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019 09 17; 93(12):e1193-e1204.
    View in: PubMed
    Score: 0.006
  22. Variation in SIPA1L2 is correlated with phenotype modification in Charcot- Marie- Tooth disease type 1A. Ann Neurol. 2019 03; 85(3):316-330.
    View in: PubMed
    Score: 0.006
  23. Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. Muscle Nerve. 2019 01; 59(1):70-75.
    View in: PubMed
    Score: 0.006
  24. Heterogeneity in gut microbiota drive polyphenol metabolism that influences a-synuclein misfolding and toxicity. J Nutr Biochem. 2019 02; 64:170-181.
    View in: PubMed
    Score: 0.006
  25. TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature. 2018 11; 563(7732):508-513.
    View in: PubMed
    Score: 0.006
  26. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017 05 01; 56(5):787-794.
    View in: PubMed
    Score: 0.005
  27. Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron. 2017 Apr 05; 94(1):93-107.e6.
    View in: PubMed
    Score: 0.005
  28. Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. Acta Neuropathol Commun. 2017 03 22; 5(1):24.
    View in: PubMed
    Score: 0.005
  29. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017 Feb; 81(2):227-239.
    View in: PubMed
    Score: 0.005
  30. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2017 04; 76(4):681-687.
    View in: PubMed
    Score: 0.005
  31. Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016 03 03; 3(1):67-75.
    View in: PubMed
    Score: 0.005
  32. Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain. 2015 Nov; 138(Pt 11):3180-92.
    View in: PubMed
    Score: 0.005
  33. Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy. Am J Hum Genet. 2014 Sep 04; 95(3):332-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.